These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9022900)

  • 21. Drug interactions with fibric acids.
    Lozada A; Dujovne CA
    Pharmacol Ther; 1994 Aug; 63(2):163-76. PubMed ID: 7809177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drugs recently released in Belgium. Mefloquine--ciprofibrate.
    Harvengt C
    Acta Clin Belg; 1991; 46(2):117-9. PubMed ID: 1649529
    [No Abstract]   [Full Text] [Related]  

  • 23. [The treatment of chronic ischemic heart disease: the potentials for hypolipidemic correction using current drugs].
    Tashchuk VK; Makoviĭchuk IO; Bilets'kyĭ SV; Hrechko SI; Polishchuk OIu; Turubarova NA
    Lik Sprava; 1998; (5):101-3. PubMed ID: 9793321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism.
    Liberopoulos E; Miltiadous G; Elisaf M
    Diabetes Obes Metab; 2001 Apr; 3(2):97-8. PubMed ID: 11298731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effect of Testosterone and Fenofibrate, Administered Alone or in Combination, on Cardiometabolic Risk Factors in Men with Late-Onset Hypogonadism and Atherogenic Dyslipidemia.
    Krysiak R; Gilowski W; Okopien B
    Cardiovasc Ther; 2015 Oct; 33(5):270-4. PubMed ID: 26031507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
    Rizzo M; Berneis K
    Curr Med Res Opin; 2007 May; 23(5):1103-11. PubMed ID: 17519077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of various fibrates on serum alkaline phosphatase activity.
    Ganotakis E; Tsimihodimos V; Bairaktari E; Rizos E; Athyros V; Seferiades C; Elisaf M
    Atherosclerosis; 2002 Nov; 165(1):187-8. PubMed ID: 12208487
    [No Abstract]   [Full Text] [Related]  

  • 28. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
    Kockx M; Princen HM; Kooistra T
    Thromb Haemost; 1998 Dec; 80(6):942-8. PubMed ID: 9869165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene.
    Raposo HF; Patrício PR; Simões MC; Oliveira HC
    J Nutr Biochem; 2014 Jun; 25(6):669-74. PubMed ID: 24746832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Mikhailidis DP; Jagroon IA
    Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of familial combined hyperlipidemia].
    Bruckert E
    Ann Endocrinol (Paris); 1997; 58(4):297-301. PubMed ID: 9436478
    [No Abstract]   [Full Text] [Related]  

  • 33. Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia.
    Flores-Castillo C; Zamora-Pérez JÁ; Carreón-Torres E; Arzola-Paniagua A; Aguilar-Salinas C; López-Olmos V; Fragoso JM; Luna-Luna M; Rodríguez-Pérez JM; Franco M; Vargas-Alarcón G; Pérez-Méndez Ó
    Fundam Clin Pharmacol; 2015 Aug; 29(4):362-70. PubMed ID: 25982284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Field of confusion: future prospects for fibrate therapy in cardiovascular disease.
    Rosenson RS
    Curr Atheroscler Rep; 2006 May; 8(3):219-22. PubMed ID: 16640958
    [No Abstract]   [Full Text] [Related]  

  • 35. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate.
    Beghin L; Capps N; Duhal N; Davies J; Staels B; Luc G
    Ann Clin Biochem; 1999 Jul; 36 ( Pt 4)():523-5. PubMed ID: 10456219
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
    Rizos E; Kostoula A; Elisaf M; Mikhailidis DP
    Angiology; 2002; 53(3):273-7. PubMed ID: 12025914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Does hypothyroidism predispose muscular toxicity of fibrates?].
    Tregouet B
    Rev Med Interne; 1991; 12(2):159. PubMed ID: 1853004
    [No Abstract]   [Full Text] [Related]  

  • 38. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
    Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
    Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Does hypothyroidism potentialize muscular toxicity of fibrates?].
    Harlé JR; Toussirot E; Disdier P; Drancourt M; Weiller PJ
    Rev Med Interne; 1990; 11(4):336. PubMed ID: 2096444
    [No Abstract]   [Full Text] [Related]  

  • 40. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?
    Colhoun H
    Lancet; 2005 Nov; 366(9500):1829-31. PubMed ID: 16310536
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.